Baseline characteristics of the patients
| Characteristic . | Treatment group . | |
|---|---|---|
| Rasburicase . | Allopurinol . | |
| Registered | ||
| Total | 27 | 25 |
| Hyperuricemic | 10 | 9 |
| Leukemia | 20 | 19 |
| Lymphoma | 7 | 6 |
| Race | ||
| White | 16 | 18 |
| Other | 11 | 7 |
| ECOG score | ||
| < 1 | 24 | 21 |
| 2-3 | 3 | 4 |
| Sex (M/F) | 16:11 | 18:7 |
| Age (y) (range) | 7.1 (0.3-17) | 7.8 (0.5-16) |
| Tumor burden | ||
| LDH—Lymphoma patients (U/L)* | 1599 ± 1022 | 1393 ± 1438 |
| WBC—Leukemia patients (109/L)* | 83.2 ± 81.0 | 91.0 ± 115.0 |
| Presentation uric acid (mg/dL)* | ||
| Total | 7.7 ± 3.5 | 6.8 ± 3.4 |
| Hyperuricemic | 11.7 ± 2.55 | 10.8 ± 3.0 |
| Leukemia | 8.2 ± 3.7 | 7.6 ± 3.7 |
| Lymphoma | 6.4 ± 2.6 | 4.8 ± 1.3 |
| Other presentation metabolic parameters (mg/dL)* | ||
| Creatinine | 0.60 ± 0.33 | 0.61 ± 0.30 |
| Phosphorus | 4.62 ± 1.39 | 4.15 ± 1.11 |
| Potassium | 4.18 ± 0.71 | 3.85 ± 0.52 |
| Calcium | 8.92 ± 0.74 | 8.67 ± 0.70 |
| Characteristic . | Treatment group . | |
|---|---|---|
| Rasburicase . | Allopurinol . | |
| Registered | ||
| Total | 27 | 25 |
| Hyperuricemic | 10 | 9 |
| Leukemia | 20 | 19 |
| Lymphoma | 7 | 6 |
| Race | ||
| White | 16 | 18 |
| Other | 11 | 7 |
| ECOG score | ||
| < 1 | 24 | 21 |
| 2-3 | 3 | 4 |
| Sex (M/F) | 16:11 | 18:7 |
| Age (y) (range) | 7.1 (0.3-17) | 7.8 (0.5-16) |
| Tumor burden | ||
| LDH—Lymphoma patients (U/L)* | 1599 ± 1022 | 1393 ± 1438 |
| WBC—Leukemia patients (109/L)* | 83.2 ± 81.0 | 91.0 ± 115.0 |
| Presentation uric acid (mg/dL)* | ||
| Total | 7.7 ± 3.5 | 6.8 ± 3.4 |
| Hyperuricemic | 11.7 ± 2.55 | 10.8 ± 3.0 |
| Leukemia | 8.2 ± 3.7 | 7.6 ± 3.7 |
| Lymphoma | 6.4 ± 2.6 | 4.8 ± 1.3 |
| Other presentation metabolic parameters (mg/dL)* | ||
| Creatinine | 0.60 ± 0.33 | 0.61 ± 0.30 |
| Phosphorus | 4.62 ± 1.39 | 4.15 ± 1.11 |
| Potassium | 4.18 ± 0.71 | 3.85 ± 0.52 |
| Calcium | 8.92 ± 0.74 | 8.67 ± 0.70 |
All values are mean ± SD; there were no significant differences comparing baseline values between treatment groups.